[Clinical results with a new intravenous immunoglobulin preparation (author's transl)].
A new immunoglobulin preparation (Sandoglobulin) was administered to 20 patients, a total of 49 infusions at a dose averaging 12.6 gamma-globulin per infusion. Twelve patients had congenital or acquired immunoglobulin deficiency, in come of them very severe. A In-vivo recovery, on the basis of an estimated plasma volume, averaged 85% of expected values. Half-life on repeat substitutions was over 20 days. There were no severe side-effects or changes in important biochemical values. In one woman with an antibody deficiency syndrome fever regularly developed after several infusions, but it always fell to normal spontaneously after several hours. In two women followed for some time, both with severe antibody-deficiency syndrome, there was a definite decrease in severity and frequency of pulmonary infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D005334:Fever / Q000139:chemically induced; D006207:Half-Life; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D007136:Immunoglobulins
Klinische Erfahrungen mit einem neuen intravenös applizierbaren Immunglobulin-Präparat.